7.71  -0.04 (-0.52%)		09-25 15:10
Open: 7.765 High: 7.99 Volume: 117,023		Pre. Close: 7.75 Low: 7.64 Market Cap: 96(M)

Short term
Mid term
Targets	6-month :	9.38	1-year :	10.96
Resists	First :	8.03	Second :	9.38
Pivot price	6.54
Supports	First :	6.35	Second :	5.3
MAs	MA(5) :	7.42	MA(20) :	6.4
	MA(100) :	6.9	MA(250) :	5.54
MACD	MACD :	0.3	Signal :	0.1
%K %D	K(14,3) :	78.7	D(3) :	75
RSI	RSI(14): 69.9
52-week	High :	9.32	Low :	2.21

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NRXS ] has closed below upper band by 12.9%. Bollinger Bands are 162.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	7.47 - 7.51	7.51 - 7.54
Low:	6.84 - 6.88	6.88 - 6.92
Close:	7.23 - 7.3	7.3 - 7.37

NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.

Wed, 16 Sep 2026
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives - Yahoo Finance

Wed, 16 Sep 2026
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference - Yahoo Finance

Tue, 15 Sep 2026
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock? - TradingView

Wed, 19 Aug 2026
Neuraxis (NRXS) grants CEO 199K instantly vesting stock units - Stock Titan

Sat, 15 Aug 2026
Neuraxis Inc. (NRXS) Q2 2026 Earnings: Narrower Loss Beats Expectations as Stock Holds Steady - Core Business Growth - careplusvn.com

Tue, 04 Aug 2026
NeurAxis Expands Payer Coverage with New Policies - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.